You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live



▲  2nd Inning 0 outs

Around the Region

Biogen’s Hemophilia drug awaits approval

Biogen Idec Inc., the Weston biotechnology company known for its drugs to treat multiple sclerosis drugs, is seeking US regulatory approval for a long-lasting treatment for hemophilia A, a rare inherited disorder that impairs blood clotting.

Current treatments can require a patient to get three or four injections a week. Biogen Idec’s hope is that a patient would need one or two injections per week.

Continue reading below

If approved, the treatment would be the first major advance­ for hemophilia A patients­ in more than two decades, the company said.

In a press release, the company said it is seeking Food and Drug Administration approval to the market recombinant factor VIII Fc fusion protein (rFVIIIFc) for the treatment of hemophilia A.

Chris Reidy can be reached at
Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of